【摘要】 目的 采用系統評價方法，評估干擾素（IFN）治療蕈樣霉菌病（MF）的療效及安全性。 方法 計算機檢索截止2010年5月的Cochrane協作網系統評價方法，納入所有比較IFN與其他方法治療MF的隨機對照試驗及臨床對照試驗進行質量評價，采用RevMan 5.0.24軟件進行Meta分析。 結果 共納入6篇符合標準的已發表文獻，包括142例受試者。Meta分析結果顯示: IFN-α單獨使用對MF的療效優于安慰劑組[OR=69.36，95%CI（3.71～1 296.64）]及地精丹方劑[OR=35.53，95%CI（1.78～710.56）]；而IFN-α與胸腺肽[OR=15.11，95%CI（0.71～322.61）]及IFN-α+阿維A酯[OR=3.10，95%CI（0.79～12.12）]的臨床療效差異無統計學意義；IFN-γ聯合窄譜中波紫外線（NB-UVB）治療與單用NB-UVB的臨床療效差異無統計學意義[OR=15.00，95%CI （0.46～485.32）]。90%的患者出現輕度“流感樣癥狀” 的不良反應，多可緩解及消退。 結論 IFN是目前治療MF的一線用藥，療效確切且大部分患者耐受性較好。【Abstract】 Objective To evaluate the clinical efficacy and side effects of interferon (IFN) in the treatment of mycosis fungoides (MF) with the method of systematic review. Methods According to the Cochrane reviewer’s handbook, all the clinical controlled trials involving mycosis fungoides being treated with interferon were retrieved. The Cochrane Collaboration’s software RevMan 5.0.24 was used for meta-analysis. Results Only six papers including 142 patients met the inclusion criteria. Meta-analyses indicated the results as follows: IFN-α monotherapy was more effective than placebo [OR=69.36,95% CI (3.71-1 296.64)] and a traditional Chinese medicine (Di-jing-dan) [OR=35.53,95% CI (1.78-710.56)], but no significant difference was found between INF-α and thymic peptide [OR=15.11, 95% CI (0.71-322.61)], and between IFN-α monotherapy and IFN-α combined with etretinate therapy [OR=3.10, 95% CI (0.79-12.12)]; and there was no significant difference between the efficacy of IFN-γ combined narrowband ultraviolet B (NB-UVB) therapy and that of single NB-UVB therapy [OR=15.00, 95% CI (0.46-485.32)]; Influenza-like side effects occurred to 90% of all the patients, which were usually slight and easy to release. Conclusion Although there are some mild side effects, interferon is safe to treat MF.
